The study concluded: "If physicians prescribe requested drugs despite personal reservations, sales may increase but appropriateness of prescribing may suffer. Concerns about the value of opening up the regulatory environment to permit direct-to-consumer advertising in the EU and Canada seem well justified."
In a related study, Mintzes conducted a survey of 150 drug-policy experts from Canada, New Zealand and the United States on the impact of DTCA on the treatment of patients, healthcare costs and patient/physician communications, 106 (71%) of whom responded.
A majority of respondents, from Canada, the US and New Zealand believed that the quality of information provided through DTCA is poor, that the effects on appropriateness of care are likely to be negative and that healthcare costs will increase as a result of increased prescribing of DTCA products.
These two studies suggest that DTCA increases the likelihood that a conversation about a specific drug will be initiated by a patient. Once such a conversation is initiated, there is a high probability that a prescription for the product will result, and an even chance that the prescribing physician will be ambivalent about that prescription. Since the aim of DTCA is to promote sales of a specific product, and the information contained in DTCA is always incomplete, and at times misleading, this research suggests that relaxing the current Canadian regulations governing DTCA of prescription drugs may not be in the best interests of patients. Given this, it is no surprise that the European Union recently decided not to support a proposal for partial introduction of DTCA involving drugs for AIDS, asthma and diabetes. The real surprise is that the matter is still under debate in Canada.
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